HC Wainwright Reaffirms “Buy” Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $158.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 112.00% from the stock’s previous close.

A number of other research firms also recently weighed in on DNTH. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Wedbush upped their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Truist Financial increased their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $129.83.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock traded down $0.23 during midday trading on Thursday, hitting $74.53. 943,572 shares of the stock were exchanged, compared to its average volume of 930,367. Dianthus Therapeutics has a 1 year low of $32.22 and a 1 year high of $117.88. The firm has a market cap of $4.08 billion, a P/E ratio of -17.96 and a beta of 1.35. The company has a 50 day moving average price of $100.75 and a two-hundred day moving average price of $94.49.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, analysts predict that Dianthus Therapeutics will post -3.81 EPS for the current year.

Insider Buying and Selling

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares in the company, valued at $326,553.90. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Adam Veness sold 16,167 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president directly owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. The trade was a 80.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 242,429 shares of company stock worth $26,118,913. Company insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. ABS Investment Management LLC acquired a new position in Dianthus Therapeutics during the second quarter valued at $194,960,000. PNC Financial Services Group Inc. boosted its position in Dianthus Therapeutics by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after acquiring an additional 139 shares during the period. GAMMA Investing LLC grew its stake in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after acquiring an additional 254 shares in the last quarter. First Horizon Corp purchased a new position in Dianthus Therapeutics during the 1st quarter valued at about $32,000. Finally, EFG International AG acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $49,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.